Search results for: Professor Adrian Towse
Filter search results
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…Towse Adrian Towse presented on Equity Adjusted QALYs? QALYs and Equity. In this presentation he: Looked at definitions of equity, drawing on work by Tony Culyer; Gave his view of…
Presentations and Posters from ISPOR Europe 2016
24 November 2016
…Speakers: Adrian Towse (OHE), Sabine Vogler (Austrian Public Health Institute), Jo De Cock (National Institute of Health and Disability Insurance), Elias Mossialos (LSE). This plenary session explored options for a…
Postdoctoral Position in The Economics of Life Sciences R&D
27 June 2017
The Structural Genomics Consortium Oxford, University of Oxford, in collaboration with OHE (Prof Adrian Towse) and Dr Jorge Mestre-Ferrandiz, is recruiting for a Postdoctoral Position in “The Economics of life…
OHE at ISPOR 2018
16 May 2018
…Health Decision Making. OHE’s Adrian Towse, Paula Lorgelly, and David Mott will be contributing to the programme. Short course: Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical…
Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
1 August 2018
This OHE Research paper by Karla Hernandez-Villafuerte, (German Cancer Research Center, DKFZ), Bernarda Zamora (OHE) and Adrian Towse (OHE) sets out a research agenda proposing new approaches in three areas…
How Should the World Pay for a COVID-19 Vaccine?
1 July 2020
This year’s OHE lecture addresses the question: how should the world pay for a COVID-19 vaccine? Adrian Towse, Emeritus Director of OHE and Senior Research Fellow presents the challenges that…
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings. A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian…
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
Share this: Download publication Adrian Towse Lotte Steuten An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination…